Pfizer and Shangyao Holdings have reached a strategic cooperation to jointly create a new format of high-quality preventive immunization services
芊芊551
发表于 2024-9-27 13:17:12
173
0
0
On September 26th, Pfizer Investment Co., Ltd. (Pfizer) and Shangyao Holdings Co., Ltd. (Shangyao Holdings) signed a strategic cooperation framework agreement. The two parties will focus on the vaccine field and carry out long-term cooperation in product promotion, innovative product introduction, and policy research. Based on their respective advantages, we will explore strategic partnerships to deepen the commercial promotion of upgraded vaccine products, accelerate the introduction of innovative products, and deepen cooperation in policy research and capacity training, in order to support the vigorous development of China's medical public health service industry and disease control, and better assist in disease prevention and health improvement for people at all stages of life.
Jean Christophe Pointeau, President of Pfizer China, said, "This strong partnership between Pfizer and Commercial Holdings will leverage their respective strengths to scientifically empower the promotion and popularization of innovative vaccines, enabling internationally leading innovative vaccines to benefit more Chinese people, comprehensively improve the health level of the nation, and become another new quality productivity in the reform of the disease control system, contributing to the achievement of the 'Healthy China 2030' strategic goal
Under the guidance of favorable policies, the domestic biopharmaceutical industry has entered the 'fast lane' of development and achieved all-round development. We are pleased to work together with Pfizer to further improve the coverage and accessibility of innovative vaccines, enhance the quality of life cycle immunization services, and realize a new format of preventive immunization health services that is fair, accessible, systematic, and sustainable, benefiting more Chinese patients and supporting the reform of China's medical system and the development of public health
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- The first weekly long-acting hemophilia therapy has been approved by the FDA from Pfizer
- Xinhua News Agency: Pinduoduo Helps' Made in China 'Go Global with High Quality
- Pfizer Beijing R&D Center settles in BioPark, Beijing Medical Innovation Park
- Starbucks releases fourth quarter financial report, achieving high-quality, profitable, and sustainable development in the Chinese market
- Pfizer will make an appearance at the 7th CIIE and make a commitment to its development for the next five years
- Pfizer's innovative targeted therapy drug Taizena has been approved in China
- Exhibits become commodities in seconds! Prostate cancer new drug approved in China, Pfizer Wang Yu: promoting China's new drug market to synchronize with the global market
- Exploring the CIIE | New products from Sinogen, Roche, and Pfizer become highlights of the CIIE
- Pfizer plans to sell hospital drug division, company responds
- After closing factories and laying off employees, Pfizer is reportedly considering selling its hospital drug division
-
美东时间周五,美股三大指数集体收涨,截止收盘,道指涨0.97%,本周累涨1.96%;纳指涨0.16%,本周累涨1.73%;标普500指数涨0.35%,本周累涨1.68%。 大型科技股涨跌不一,特斯拉涨近4%,微软涨1%,苹果、奈飞 ...
- budingmm
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
新华财经上海11月23日电默沙东与中国癌症基金会23日签署中国低卫生资源地区宫颈癌综合防控项目捐赠协议,将聚焦加速消除宫颈癌这一目标,计划在未来两年由默沙东向中国癌症基金会捐赠共计8.1万支HPV疫苗。 ...
- 逸风宝宝
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
11月21日晚,路特斯(LOT.US)公布2024年第三季度财报。1—9月,路特斯总交付量共有7617辆,同比增长136%。此外,公司前九个月总收入为6.53亿美元,同比增长翻番。 具体来看,路特斯全球各主要市场交付比例 ...
- 接通无语语sw
- 3 天前
- 支持
- 反对
- 回复
- 收藏
-
11月23日,香港科技大学举行荣誉博士学位颁授典礼及博士毕业典礼,其中向英伟达创始人兼CEO黄仁勋颁授工程学荣誉博士,称赞其带领英伟达在加速运算领域取得杰出成果,研发的GPU重新定义电脑视觉体验并为人工智能 ...
- 寒武季节俨
- 3 天前
- 支持
- 反对
- 回复
- 收藏